Manhattan Scientifics Reaches the Fork (Falk) in the Road
August 19 2014 - 8:39AM
Business Wire
Turns to a marketing wizard behind Viagra and
Celebrex to commercialize its MRX technology
Spencer Falk, whose marketing expertise was mission-critical to
the blockbuster success of Viagra and Celebrex, among other medical
brands, today announced that he would lead the commercialization of
early cancer detection technology for Senior Scientific, a division
of Manhattan Scientifics (OTCQB:MHTX). Mr. Falk previously held
senior marketing positions at Pfizer and Forest Laboratories, and
has had a 35-year career in the pharmaceutical and diagnostic
sector fields.
Gerald Grafe, president of Senior Scientific, commented, “We’re
in the rapid, early-detection business, and the fastest way we know
for top corporate partners to detect us is via Mr. Falk’s sterling
position in the medical device and pharmaceutical industry.”
Spencer Falk’s personal contacts include senior management
professionals leading oncology product development at firms
including Merck, Astra-Zeneca/Medimmune, Pfizer, Esai, Johnson
& Johnson and others. Mr. Falk will replace Loraine Upham.
Mr. Falk had been responsible for introducing Senior Scientific
to the key oncology researchers at the MD Anderson Cancer Research
Hospital, which led to their undertaking validation studies. MD
Anderson received and is testing Senior Scientific’s first
early-detection device (called “MRX”). The technology, developed by
Edward R. Flynn, PhD, provides the most specific and most sensitive
method for detecting cancer currently known.
“On its basic level, MRX technology works like an ambulance,”
says Falk. “It saves lives by connecting patients with their
required treatments in less time. But it does more: it has the
potential to shift the paradigm in the rapidly expanding field of
personalized medicine, where MRX may enable targeted therapies to
achieve higher cure rates in appropriate patients. For these
reasons, I believe Senior Scientific’s technology may be in great
demand from multiple sectors wishing to harness both speed and
precision in “next generation” therapies."
Marvin Maslow, founder of Manhattan Scientifics, said, “Nothing
succeeds like success so we recruited Spencer Falk. His addition to
our team accelerates our drive to commercialization significantly.
With Spencer and (president) Gerald Grafe’s leadership, we’ve
assembled the capital, the technology and the determination behind
just about every success story we know. Now Senior Scientific can
proceed -full speed towards doing good and doing well.”
“The entire Manhattan Scientifics team is delighted to welcome
Spencer Falk,” said Manny Tsoupanarias, CEO of Manhattan
Scientifics. “He shares our passion and vision for the future of
both cancer diagnostic technology and personalized medicine. With
Spencer’s help, we expect to achieve market leadership positions is
far less time, and with his track record for creating exceptional
value we expect to delight our shareholders.”
About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com) is located in
New Mexico, New York and Montreal. It is focused on technology
transfer and commercialization of transformative technologies in
the nano medicine space. The company is presently developing
commercial medical prosthetics applications for its ultra-fine
grain metals and plans to commercialize the cancer research work
and nano medical applications developed by Senior Scientific LLC, a
unit of the Company.
Forward-looking statement
This press release contains forward-looking statements, which
are subject to a number of risks, assumptions and uncertainties
that could cause the Company's actual results to differ materially
from those projected in such forward-looking statements. Management
at Manhattan Scientifics believes that purchase of its shares
should be considered to be at the high end of the risk spectrum.
Forward-looking statements speak only as of the date made and are
not guarantees of future performance. We undertake no obligation to
publicly update or revise any forward-looking statements.
Manhattan Scientifics, Inc. PR & IRMarvin Maslow,
917-923-3300marvin@mhtx.comorCorporate Advisory/PRFastnet
AdvisorsAnthony Furey,
631-665-1234mtfurey@fastnetadvisors.comorHawk AssociatesFrank
Hawkins, 305-451-1888f.hawkins@hawkassociates.comorEuropean
Contact:Herbert Strauss, +43-316-296-316herbert "at" eu-ir.com
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Apr 2024 to May 2024
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From May 2023 to May 2024